-
Sector Analysis
NewAutomotive: Hiring Trends & Signals Q1 2024
The Automotive: Hiring Trends & Signals Q1 2024 report provides valuable insights into hiring trends, job listings, and other important information. The report aims to support decision-making by providing a competitive advantage and a deeper understanding of employment trends, roles, skills, locations, and themes. It delivers critical job insights to corporations and talent/staffing platforms. The report enables competitive analytics and intelligence through proxy signals from job roles, locations, themes and skills. It helps corporations and academia anticipate the future of...
-
Company Insights
NewDeere & Company – Digital Transformation Strategies
Deere & Company Digital Transformation Strategies Report Overview Deere & Company (John Deere) has been focusing on using artificial intelligence, the Internet of Things (IoT), cloud-based mobile applications, big data, and drones to digitally transform its operations. The annual ICT spending of John Deere was estimated at $3.6 billion for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. John Deere is a provider of advanced products and services. It manufactures...
-
Track & Monitor
NewArtificial intelligence in oil & gas: oil exploration AI
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the oil & gas industry’s oil exploration AI segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Product Insights
NewNet Present Value Model: Johnson & Johnson’s Gemcitabine
Empower your strategies with our Net Present Value Model: Johnson & Johnson's Gemcitabine report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Johnson & Johnson’s Nipocalimab
Empower your strategies with our Net Present Value Model: Johnson & Johnson's Nipocalimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Thematic Analysis
NewGlobal M&A Deals in Q1 2024 – Top Themes by Sector – Thematic intelligence
The global M&A market in Q1 2024 witnessed deals worth $613 billion, a rise of 38% compared to Q1 2024. In terms of deal volume, there was a 13% fall from 8,468 deals in Q1 2023 to 7,248 M&A deals in Q1 2024. The TMT sector led the M&A deal activity, with 2,163 deals worth $186 billion recorded in Q1 2024. Most sectors saw a year-on-year increase in deal activity in Q1 2024. Mega-deals (defined as any deal valued at...
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Ulevostinag
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Ulevostinag report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Tulisokibart
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Tulisokibart report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merck & Co Inc’s Efinopegdutide
Empower your strategies with our Net Present Value Model: Merck & Co Inc's Efinopegdutide report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Shionogi & Co Ltd’s Zatolmilast
Empower your strategies with our Net Present Value Model: Shionogi & Co Ltd's Zatolmilast report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.